Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content

Middle East

Bahrain approves emergency use for regn-cov2 medicine -BNA

1 minute read

CAIRO, June 16 (Reuters) - Bahrain on Wednesday approved the emergency use for regn-cov2 medicine, Regeneron Pharmaceuticals Inc’s (REGN.O) and Roche's newly authorized COVID-19 antibody combination, as part of its coronavirus treatment protocol to treat existing cases with mild and moderate symptoms, the state news agency (BNA) reported.

The report said updating the corona treatment protocol in the kingdom would reduce symptoms complications.

Reporting by Alaa Swilam Editing by Chris Reese

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters